These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 37354090)

  • 21. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
    Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
    Haddad FG; Kantarjian H
    J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
    Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
    Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
    Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Khoury HJ; Bixby DL
    Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
    Cha SH; Kim K; Song YK
    Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
    Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
    [No Abstract]   [Full Text] [Related]  

  • 32. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.
    Kota VK; Kong JH; Arellano M; El Rassi F; Gaddh M; Heffner LT; Winton EF; Jillella AP; McLemore ML; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e71-e73. PubMed ID: 29032022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted drugs in chronic myeloid leukemia.
    Gora-Tybor J; Robak T
    Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic myeloid leukemia].
    Usui N
    Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
    Breccia M; Chiodi F; Nardozza AP; Valsecchi D; Perrone V; Sangiorgi D; Giacomini E; Rendace MC; Coco P; Premoli E; Degli Esposti L
    Adv Ther; 2023 Mar; 40(3):961-974. PubMed ID: 36562943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
    Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I
    Cancer Sci; 2020 Oct; 111(10):3714-3725. PubMed ID: 33404088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
    Jabbour E; Kantarjian H
    Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.
    Sönmez Ö; Özgür Yurttaş N; İhtiyaroğlu İ; Çakır HM; Atlı Z; Elverdi T; Salihoğlu A; Seyahi N; Ar MC; Öngören Ş; Başlar Z; Soysal T; Eşkazan AE
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):232-239. PubMed ID: 38281820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
    Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
    Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.